Jim Cramer Says “Look, in the End, There’s Eli Lilly and There’s Everybody Else”

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer mentioned the stock during the episode and commented:

“I do believe that there are very few biotechs that I really want to buy right now because they’re so picked over. Look, in the end, there’s Eli Lilly and there’s everybody else.”

Pixabay/Public Domain

Eli Lilly and Company (NYSE:LLY) develops medicines for diabetes, obesity, cancer, autoimmune disorders, and neurological conditions. Cramer discussed the stock during the October 30 episode and highlighted its solid GLP-1 revenue, as he said:

“Or how about the drug companies? Holy cow, remember them? They used to be big and important, weren’t they? Eli Lilly reported this morning, and their GLP-1 complex, you know, the weight loss diabetes thing, made a billion dollars more than Wall Street expected. That’s tech-like. When I first saw it, I was thinking, okay, the market won’t care. Big yawner. We own Lilly for the trust, we believe in it, but we feel like we’re dopes lately.

But you know what? I knew that Dave Ricks, the CEO, was going to be on Squawk on the Street. I said, hey, listen, maybe something good will happen here… maybe, I’m too jaded, right? I just assumed nobody will care because it’s pharma, a group that nobody seems to want in this environment. Apparently, I was wrong. That’s right. Eli Lilly’s stock rallied nearly 4% today. I think we have Meta’s weakness to thank for that gain.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.